OSERO Study Examines Treatment Sequencing of Regorafenib and FTD/TPI in Metastatic CRC

▸ TREATMENT

The OSERO study was a prospective observational study in patients with metastatic colorectal cancer scheduled for later-line treatment with regorafenib or trifluridine/tipiracil (FTD/TPI), with or without bevacizumab. (British Journal of Cancer)